Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A

AIDS Research and Human Retroviruses

Volumn 22, Issue 6, 2006, Pages 569-579

  Beddows, Simon ^a   Kirschner, Marc ^a   Campbell Gardener, Lila ^a   Franti, Michael ^b   Dey, Antu K ^a   Iyer, Sai Prasad N ^b   Maddon, Paul J ^b   Paluch, Maciej ^a   Master, Aditi ^a   Overbaugh, Julie ^c   VanCott, Thomas ^d,e   Olson, William C ^b   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

AFRICA; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENVELOPE GENE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; SOLUBILITY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AFRICA, EASTERN; AIDS VACCINES; ANIMALS; CELL LINE; DIMERIZATION; DRUG DESIGN; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV-1; HUMANS; MICE; NEUTRALIZATION TESTS; RABBITS;

EID: 33745726588     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.569     Document Type: Article

References (80)

1. McCutchan FE: Understanding the genetic diversity of HIV-1. AIDS 2000;14(Suppl 3):S31-S44.
2. Robertson DL, Anderson JP, Bradac JA, et al.: HIV-1 nomenclature proposal. Science 2000;288:55-56.
3. Perrin L, Kaiser L, and Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3:22-27.
4. UNAIDS: AIDS Epidemic Update 2004. www.unaids.org.
5. Dowling WE, Kim B, Mason CJ, et al.: Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS 2002;16:1809-1820.
6. Yang C, Li M, Shi YP, et al.: Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya. AIDS Res Hum Retroviruses 2004;20:565-574.
7. Neilson JR, John GC, Carr JK, et al.: Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999;73:4393-4403.
8. Louwagie J, Janssens W, Mascola J, et al.: Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol 1995;69:263-271.
9. Desrosiers RC: Prospects for an AIDS vaccine. Nat Med 2004;10:221-223.
10. Garber DA, Silvestri G, and Feinberg MB: Prospects for an AIDS vaccine: Three big questions, no easy answers. Lancet Infect Dis 2004;4:397-413.
11. Graham BS: Clinical trials of HIV vaccines. Annu Rev Med 2002;53:207-221.
12. Klausner RD, Fauci AS, Corey L, et al.: The need for a global HIV vaccine enterprise. Science 2003;300:2036-2039.
13. McMichael AJ and Hanke T: HIV vaccines 1983-2003. Nat Med 2003;9:874-880.
14. Brown BK, Darden JM, Tovanabutra S, et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005;79:6089-6101.
15. Gao F, Weaver EA, Lu Z, et al.: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005;79:1154-1163.
16. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
17. Jeffs SA, Goriup S, Kebble B, et al.: Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004;22:1032-1046.
18. Chakrabarti BK, Kong WP, Wu BY, et al.: Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76:5357-5368.
19. Srivastava IK, Stamatatos L, Legg H, et al.: Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002;76:2835-2847.
20. Yang X, Florin L, Farzan M, et al.: Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000;74:4746-4754.
21. Yang X, Lee J, Mahony EM, et al.: Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76:4634-4642.
22. Zhang CW, Chishti Y, Hussey RE, and Reinherz EL: Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol Chem 2001;276:39577-39585.
23. Binley JM, Sanders RW, Clas B, et al.: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000;74:627-643.
24. Gallo SA, Finnegan CM, Viard M, et al.: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003;1614:36-50.
25. Poignard P, Saphire EO, Parren PW, and Burton DR: gp120: Biologic aspects of structural features. Annu Rev Immunol 2001;19:253-274.
26. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
27. D'Souza MP, Livnat D, Bradac JA, and Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 1997;175:1056-1062.
28. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
29. Trkola A, Pomales AB, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
30. Trkola A, Purtscher M, Muster T, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
31. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
32. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
33. Parren PW, Moore JP, Burton DR, and Sattentau QJ: The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS 1999;13(Suppl. A):S137-S162.
34. Graham BS and Mascola JR: Lessons from failure-preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005;191:647-649.
35. Gilbert PB, Peterson ML, Follmann D, et al.: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-677.
36. Flynn NM, Forthal DN, Harro CD, et al.: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
37. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5:233-236.
38. Center RJ, Lebowjtz J, Leapman RD, and Moss B: Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 2004;78:2265-2276.
39. Si Z, Phan N, Kiprilov E, and Sodroski J: Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 2003;19:217-226.
40. Schulke N, Vesanen MS, Sanders RW, et al.: Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002;76:7760-7776.
41. Herrera C, Klasse PJ, Michael E, et al.: The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005;338:154-172.
42. Pancera M and Wyatt R: Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005;332:145-156.
43. Binley JM, Sanders RW, Master A, et al.: Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002;76:2606-2616.
44. Sanders RW, Vesanen M, Schuelke N, et al.: Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002;76:8875-8889.
45. Beddows S, Schulke N, Kirschner M, et al.: Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005;79:8812-8827.
46. Long EM, Martin HL Jr, Kreiss JK, et al.: Gender differences in HIV-1 diversity at time of infection. Nat Med 2000;6:71-75.
47. Poss M and Overbaugh J: Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol 1999;73:5255-5264.
48. Roben P, Moore JP, Thali M, et al.: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
49. Zwick MB, Labrijn AF, Wang M, et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905.
50. Thali M, Moore JP, Furman C, et al: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
51. Wyatt R, Moore J, Accola M, et al.: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
52. Thali M, Furman C, Ho DD, et al.: Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992;66:5635-5641.
53. Mariani R, Kirchhoff F, Greenough TC, et al.: High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol 1996;70:7752-7764.
54. Parren PW, Wang M, Trkola A, et al.: Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol 1998;72:10270-10274.
55. Trkola A, Ketas TJ, Nagashima KA, et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-588.
56. Strizki JM, Xu S, Wagner NE, et al.: SCH-C (SCH 351125), and orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
57. Marozsan AJ, Kuhmann SE, Morgan T, et al.: Generation and properties of a human immunodeficiency type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005;338:182-199.
58. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-187.
59. Fouts T, Godfrey K, Bobb K, et al.: Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 2002;99:11842-11847.
60. Herrera C, Spenlehauer C, Fung MS, et al.: Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003;77:1084-1091.
61. Si Z, Cayabyab M, and Sodroski J: Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol 2001;75:4208-4218.
62. Zwick MB, Kelleher R, Jensen R, et al.: A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol 2003;77:6965-6978.
63. Moore JP, Cao Y, Leu J, et al.: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-444.
64. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
65. Gordon CJ, Muesing MA, Proudfoot AE, et al.: Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999;73:684-694.
66. Yuan W, Craig S, Yang X, and Sodroski J: Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. Virology 2005;332:369-383.
67. Owens RJ and Compans RW: The human immunodeficiency virus type 1 envelope protein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing. Virology 1990;179:827-833.
68. Binley JM, Wrin T, Korber B, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78:13232-13252.
69. Zwick MB, Jensen R, Church S, et al.: Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005;79:1252-1261.
70. Moore JP, McCutchan FE, Poon SW, et al.: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994;68:8350-8364.
71. Moore JP, Parren PW, and Burton DR: Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001;75:5721-5729.
72. Hartley O, Klasse PJ, Sattentau QJ, and Moore JP: V3: HIVs switch-hitter. AIDS Res Hum Retroviruses 2005;21:171-189.
73. Connor RI, Sheridan KE, Lai C, Zhang L, and Ho DD: Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1996;70:5306-5311.
74. Zwick MB, Komori HK, Stanfield RL, et al.: The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004;78:3155-3161.
75. Murakami T, Ablan S, Freed EO, and Tanaka Y: Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol 2004;78:1026-1031.
76. Wyma DJ, Jiang J, Shi J, et al.: Coupling of human immunodeficiency virus type 1 fusion to virion maturation: A novel role of the gp41 cytoplasmic tail. J Virol 2004;78:3429-3435.
77. Wyss S, Dimitrov AS, Baribaud F, et al.: Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol 2005;79:12231-12241.
78. Scanlan CN, Pantophlet R, Wormald MR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha 1 → 2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-7321.
79. Ofek G, Tang M, Sambor A, et al.: Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-10737.
80. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.